CardioExchange Archive

February 10th, 2015

Risk for Sudden Death in Spironolactone Users Who Take Trimethoprim-Sulfamethoxazole

Tony Antoniou, PharmD, PhD

Tony Antoniou discusses his case-control study of elderly residents of Ontario who were users of spironolactone and died suddenly within 14 days after receiving an antibiotic prescription.

---

November 21st, 2014

Encouraging Results for Two New Drugs for Hyperkalemia

Larry Husten, PHD

Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. In a phase 3 study, published online in the New England Journal of Medicine, researchers first randomized 753 […]

---

November 21st, 2014

Encouraging Results For Two New Drugs For Hyperkalemia

Larry Husten, PHD

Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. … Click here to read the full post on Forbes.  

---

June 5th, 2014

An Adverse Event on Lisinopril: What Do You Say to Your Patient?

John Ryan, MD

In this scenario of an adverse event after taking a guideline-recommended dosage of lisinopril to lower BP, John Ryan asks, “What do you say to your patient?”

---

January 10th, 2012

Researchers Find Lower Sweet Spot for Potassium Levels in MI

Larry Husten, PHD

Current guidelines for the treatment of acute MI recommend that serum potassium be maintained between 4.0 and 5.0 mEq/L, and some believe that the upper limit could be raised to 5.5, but evidence is based on small, outdated studies. Now a study published in JAMA suggests that the ideal potassium range should be adjusted downward. Abhinav Goyal and […]

---

August 30th, 2011

New Results from EMPHASIS-HF Show Big Benefits For High-Risk Subgroups Taking Eplerenone

Larry Husten, PHD

Last November the main results of the EMPHASIS-HF trial demonstrated that eplerenone was significantly better than placebo in reducing the risk for death and hospitalization in patients with systolic heart failure and mild symptoms. Now a new analysis of the trial, presented by Bertram Pitt at the European Society of Cardiology meeting in Paris, reinforces the earlier findings […]

---